Abstract

Abstract The severe acute respiratory syndrome coronavirus (SARS‐CoV‐2) pandemic has triggered a significant impact on global public health security, it is urgent to develop effective antiviral drugs. Previous studies have found that binding to ACE2 is a key step in the invasion of SARS‐CoV‐2 into host cells, so virus invasion can be inhibited by blocking ACE2, but there are few reports on this kind of specific inhibitor. Our previous study found that Harringtonine (HT) can inhibit the entry of SARS‐CoV‐2 spike pseudovirus into ACE2 h cells, but its relatively high cytotoxicity limits its further development. Amino acid modification of the active components can increase their solubility and reduce their cytotoxicity. Therefore, in this study, seven new derivatives were synthesized by amino acid modification of its core structure Cephalotaxine. The target compounds were evaluated by cell viability assay and the SARS‐CoV‐2 spike pseudovirus entry assay. Compound CET‐1 significantly inhibited the entry of pseudovirus into ACE2 h cells and showed less cytotoxicity than HT. Molecular docking results showed that CET‐1 could bind TYR83, an important residue of ACE2, just like HT. In conclusion, our study provided a novel compound with more potential activity and lower toxicity than HT on inhibiting the SARS‐CoV‐2 spike pseudovirus infection, which makes it possible to be a lead compound as an antiviral drug in the future.